

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES



PHM005C
January 2013

Peggy Lehr
Project Analyst

ISBN: 0-89336-646-3

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
METHODOLOGY/INFORMATION SOURCES	1
INTENDED AUDIENCE	1
ANALYST CREDENTIALS	2
RELATED BCC REPORTS	2
BCC ONLINE SERVICES	2
DISCLAIMER	2
CHAPTER 2 SUMMARY	4
SUMMARY TABLE GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES, THROUGH 2017 (\$ MILLIONS)	4
SUMMARY FIGURE GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES, 2011 AND 2017 (%)	4
CHAPTER 3 INDUSTRY OVERVIEW	7
EPIDEMIOLOGY AND ETIOLOGY OF SEXUALLY TRANSMITTED DISEASES	7
TRENDS IN GLOBAL TRANSMISSION OF STDS	7
DIAGNOSIS OF STD	7
VISUAL OBSERVATION	7
BLOOD/TISSUE STAINING	8
AUTOMATED TESTING	8
TABLE 1 MAJOR MANUFACTURERS OF AUTOMATED STD TESTS, 2012	8
NONAUTOMATED STD DIAGNOSTIC TESTING	8
TABLE 2 MAJOR MANUFACTURERS OF RAPID AND LABORATORY DIAGNOSTIC STD KITS, 2012	8
VACCINES	9
TABLE 3 MAJOR MANUFACTURERS OF VACCINES FOR STDS	9
MARKET ANALYSIS BY DISEASE	9
HPV/GENITAL WARTS	10
Diagnostic Product Market	10
TABLE 4 HPV DIAGNOSTIC PRODUCTS, MANUFACTURER AND MARKET SHARE, 2011 (%)	10
GONORRHEA	10
Diagnostic Product Market	10
TABLE 5 GONORRHEA DIAGNOSTIC PRODUCT MANUFACTURERS AND PRODUCT NAMES	11
Treatment Market	11
TABLE 6 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS	11
HEPATITIS A, B AND C	12
Diagnostic Product Market	12
TABLE 7 HEPATITIS A, B AND C DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE OF TEST, 2011 (\$ MILLIONS/%)	12
Treatment Market	12
TABLE 8 MARKET STANDING OF MAJOR HEPATITIS B AND C TREATMENT MANUFACTURERS BY REVENUES, 2011 (\$ MILLIONS)	13
FIGURE 1 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011 (%)	13

TOPIC	PAGE NO.
HIV/AIDS	14
Diagnostic Market	14
<i>TABLE 9 HIV DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE, 2011 (\$ MILLIONS/%)</i>	14
Treatment Market	14
<i>TABLE 10 HIV/AIDS TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2011 (\$ MILLIONS/%)</i>	15
<i>FIGURE 2 MARKET SHARE OF LEADING COMPANIES IN THE HIV/AIDS TREATMENT MARKET, 2011 (%)</i>	15
MARKET SHARE, BY DISEASE	16
<i>TABLE 11 NUMBER OF DIAGNOSTIC AND PHARMACEUTICAL MANUFACTURERS, BY DISEASE TREATED, WITH REVENUES AND MARKET SHARE, 2011 (\$ MILLIONS/%)</i>	16
MERGERS AND ACQUISITIONS	16
<i>TABLE 12 SELECTED MERGERS AND ACQUISITIONS, 2008-2012 (\$ MILLIONS)</i>	16
CHAPTER 4 DISEASE OVERVIEW	19
<i>TABLE 13 CAUSATIVE ORGANISMS FOR SEXUALLY TRANSMITTED DISEASES</i>	19
DIAGNOSTIC TESTING	19
FLUORESCENT IMMUNOASSAY (FIA)	20
Direct Fluorescent Antibody Testing	20
Indirect Fluorescent Antibody Testing	20
Chemiluminescent Microparticle Immunoassay	20
ENZYME IMMUNOASSAY	20
Basic EIA	21
Enzyme-linked Immunosorbent Assay (ELISA)	21
GENE PROBE ANALYSIS	21
Polymerase Chain Reaction Amplification	22
Nucleic Acid Amplification Test (NAT)	22
Transcription-Mediated Amplification (TMA)	22
Nucleic Acid Sequence-Based Amplification (NASBA)	22
Dual Kinetic Assay (DKA)	23
BACTERIAL VAGINOSIS	23
OVERVIEW	23
RISK FACTORS	23
INCIDENCE	24
DIAGNOSTIC PROCEDURES	24
<i>TABLE 14 CURRENT DIAGNOSTIC TESTS FOR BACTERIAL VAGINITIS</i>	24
TREATMENTS	24
<i>TABLE 15 CURRENT TREATMENTS FOR BACTERIAL VAGINITIS</i>	25
CANDIDIASIS	25
OVERVIEW	25
RISK FACTORS	25
INCIDENCE	25
DIAGNOSTIC PROCEDURES	25
<i>TABLE 16 DIAGNOSTIC TESTS FOR CANDIDIASIS</i>	25
TREATMENT	26
<i>TABLE 17 TREATMENTS FOR VULVOVAGINAL CANDIDIASIS</i>	26
CHANCROID (VENEREAL ULCERS)	27

TOPIC	PAGE NO.
OVERVIEW	27
RISK FACTORS	27
INCIDENCE	27
DIAGNOSTIC PROCEDURES	28
TREATMENTS	28
<i>TABLE 18 CURRENT MEDICATIONS USED TO TREAT CHANCROID ULCERS</i>	28
CHLAMYDIA	28
OVERVIEW	28
RISK FACTORS	29
INCIDENCE	29
DIAGNOSTIC PROCEDURES	30
<i>TABLE 19 CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE AND MANUFACTURER, 2012</i>	30
TREATMENTS	31
<i>TABLE 20 CURRENT MEDICATIONS USED TO TREAT CHLAMYDIA</i>	31
GENITAL HERPES	32
OVERVIEW	32
RISK FACTORS	32
INCIDENCE	32
DIAGNOSTIC PROCEDURES	32
<i>TABLE 21 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPESBY BRAND NAME, TYPE AND MANUFACTURER, 2012</i>	32
TREATMENTS	33
<i>TABLE 22 CURRENT TREATMENTS FOR GENITAL HERPESBY BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012</i>	34
GENITAL WARTS/HUMAN PAPILLOMAVIRUS	34
OVERVIEW	34
RISK FACTORS	34
INCIDENCE	35
DIAGNOSTIC PROCEDURES	35
<i>TABLE 23 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME, TYPE AND MANUFACTURER, 2012</i>	35
TREATMENTS	35
<i>TABLE 24 MEDICATIONS USED TO TREAT GENITAL WARTS BY BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	36
GONORRHEA	36
OVERVIEW	36
RISK FACTORS	36
Age 15 to 24 Years	36
Black Heritage	37
Additional Risk Factors	37
INCIDENCE	37
DIAGNOSTIC PROCEDURES	37
<i>TABLE 25 CURRENT PRODUCTS USED TO DIAGNOSE GONORRHEA</i>	37
TREATMENTS	38
<i>TABLE 26 CURRENT MEDICATIONS USED TO TREAT GONORRHEA</i>	38
HEPATITIS B AND C	39
OVERVIEW	39

TOPIC	PAGE NO.
RISK FACTORS	39
INCIDENCE	39
DIAGNOSTIC PROCEDURES	40
<i>TABLE 27 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY BRAND NAME, TYPE AND MANUFACTURER, 2012</i>	40
TREATMENTS	41
<i>TABLE 28 VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2012</i>	42
HERPES SIMPLEX VIRUS (SEE GENITAL HERPES)	43
HIV/AIDS	43
OVERVIEW	43
<i>TABLE 29 CDC CLASSIFICATION OF HIV INFECTION</i>	43
RISK FACTORS	44
Condoms and Preventing HIV	44
INCIDENCE/MORTALITY	44
DIAGNOSTIC PROCEDURES	45
<i>TABLE 30 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HIV/AIDS BY BRAND NAME, TYPE AND MANUFACTURER, 2012</i>	45
TREATMENTS	46
<i>TABLE 31 HIV LIFE CYCLE</i>	46
Generic Treatments	46
<i>TABLE 32 FDA-APPROVED GENERIC DRUGS FOR TREATMENT OF HIV, 2012</i>	47
Brand Name HIV Treatments	48
<i>TABLE 33 CURRENTLY APPROVED PHARMACEUTICAL PRODUCTS FOR TREATMENT OF HIV/AIDS BY BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012</i>	48
BRANDED TREATMENT MARKET, BY MAJOR MANUFACTURER	49
<i>TABLE 34 HIV TREATMENT MARKET, BY MANUFACTURER (\$ MILLIONS)</i>	49
<i>FIGURE 3 2011 MARKET SHARE FOR BRANDED HIV DRUGS, BY MANUFACTURER (%)</i>	50
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)	50
HAART Failure	51
Mega HAART	51
PEDIATRIC HIV	51
Smaller Pediatric Market	51
Complicated Treatment Regimen	52
PEDICULOSIS PUBIS	52
OVERVIEW	52
RISK FACTORS	52
INCIDENCE	52
DIAGNOSTIC PROCEDURES	52
TREATMENTS	53
<i>TABLE 35 CURRENT TREATMENTS FOR PEDICULOSIS PUBIS BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	53
PELVIC INFLAMMATORY DISEASE (PID)	53
OVERVIEW	53
RISK FACTORS	53
INCIDENCE	54
DIAGNOSIS	54
TREATMENT	54

TOPIC	PAGE NO.
<i>TABLE 36 CURRENT TREATMENTS FOR PID BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	54
SCABIES	55
OVERVIEW	55
RISK FACTORS	55
INCIDENCE	55
DIAGNOSTIC PROCEDURES	56
TREATMENTS	56
<i>TABLE 37 CURRENT TREATMENTS FOR SCABIES BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	56
SYPHILIS	56
OVERVIEW	56
<i>TABLE 38 STAGES OF SYPHILIS</i>	57
RISK FACTORS	57
INCIDENCE	57
U.S.	58
Western Europe, Russia	58
DIAGNOSTIC PROCEDURES	58
<i>TABLE 39 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY BRAND NAME, TYPE AND MANUFACTURER, 2012</i>	58
TREATMENTS	59
TRICHOMONIASIS	59
OVERVIEW	59
RISK FACTORS	60
INCIDENCE	60
DIAGNOSTIC PROCEDURES	60
<i>TABLE 40 DIAGNOSTIC ASSAYS FOR DETECTION OF TRICHOMONAS WITH BRAND NAME, TYPE AND MANUFACTURER</i>	60
TREATMENTS	60
<i>TABLE 41 CURRENT MEDICATIONS FOR THE TREATMENT OF TRICHOMONAS</i>	61
STD TRENDS	61
GLOBAL CONDOM USE	61
U.S.	61
Gonorrhea	61
Chlamydia	61
Syphilis	61
HIV/AIDs	62
EMRA	62
Gonorrhea	62
Chlamydia	62
Hepatitis B	62
Hepatitis C	63
HIV/AIDS	63
Syphilis	63
ASIA	64
Gonorrhea	64
Chlamydia	64
HIV/AIDS	64

TOPIC	PAGE NO.
Hepatitis	64
CHAPTER 5 STD DIAGNOSIS AND TREATMENT OPTIONS	66
DIAGNOSTIC OPTIONS, BY TYPE	66
<i>FIGURE 4 MARKET SHARE FOR TYPES OF TESTS USED TO DIAGNOSE STDS, 2012 (%)</i>	66
GLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS, BY DISEASE	67
<i>TABLE 42 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT STDS BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	67
PROJECTED GLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS, BY REGION	68
<i>TABLE 43 PROJECTED GLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	68
<i>FIGURE 5 GLOBAL STD DIAGNOSTIC MARKET, BY REGION 2012 AND 2017 (%)</i>	69
STD PHARMACEUTICAL PRODUCTS, BY DISEASE	69
<i>TABLE 44 PROJECTED GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	70
GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS, BY REGION	70
<i>TABLE 45 PROJECTED GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	70
<i>FIGURE 6 GLOBAL STD PHARMACEUTICAL MARKET BY REGION 2012 AND 2017 (%)</i>	71
OPPORTUNITIES IN THE STD DIAGNOSIS AND TREATMENT MARKET	71
OPPORTUNITIES IN THE HIV/AIDS MARKET	72
Diagnostics	72
Pharmaceuticals	73
Immediate term	73
Medium-term priorities	73
OPPORTUNITIES IN THE HEPATITIS MARKET	74
Pharmaceutical Opportunities in the Hepatitis Market	74
OTHER STDS	74
Diagnostic Testing	74
CHAPTER 6 THE AMERICAS MARKET	76
DIAGNOSTIC PRODUCTS IN THE AMERICAS	76
MARKET FOR DIAGNOSTIC PRODUCTS IN THE AMERICAS	76
<i>TABLE 46 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE AMERICAS, THROUGH 2017 (\$ MILLIONS)</i>	76
<i>FIGURE 7 MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE AMERICAS BY DISEASE, 2012 AND 2017 (%)</i>	76
PHARMACEUTICAL TREATMENTS IN THE AMERICAS	78
<i>TABLE 47 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE AMERICAS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	78
<i>FIGURE 8 MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE AMERICAS BY DISEASE, 2012 AND 2017 (%)</i>	79
ANTIBIOTIC RESISTANCE IN TREATING STDS	79
THE U.S.	80
STD AND PREGNANCY	80
Problems for the Child at Birth	80
Treatments for STDs During Pregnancy	80
<i>TABLE 48 ESTIMATED ANNUAL NUMBER OF PREGNANT WOMEN WITH AN STD IN THE U.S.</i>	80
ANNUAL INCIDENCE OF STDS IN THE U.S.	81

TOPIC	PAGE NO.
<i>TABLE 49 ANNUAL INCIDENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., 2010 (PER 100,000 PEOPLE)</i>	81
Gonorrhea	81
Chlamydia	82
Syphilis	82
HIV	82
HIV and Women	82
Hepatitis B	82
Hepatitis C	82
LATIN/SOUTH AMERICA	83
HIV	83
HIV Treatment in Central/South America	83
CANADA	83
HIV IN CANADA	83
HEPATITIS IN CANADA	84
CHLAMYDIA IN CANADA	84
SYPHILIS IN CANADA	84
GONORRHEA IN CANADA	84
CHAPTER 7 THE EMRA MARKET	86
STD DIAGNOSTIC PRODUCT MARKET IN THE EMRA	86
<i>TABLE 50 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE EMRA, THROUGH 2017 (\$ MILLIONS)</i>	86
<i>FIGURE 9 MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE EMRA BY DISEASE, 2012 AND 2017 (%)</i>	86
STD PHARMACEUTICAL TREATMENTS IN THE EMRA	87
<i>TABLE 51 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE EMRA BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	87
<i>FIGURE 10 MARKET FOR STD TREATMENT PRODUCTS IN THE EMRA BY DISEASE, 2012 AND 2017 (%)</i>	88
ANNUAL INCIDENCES OF STD DISEASE IN THE EMRA	89
UNITED KINGDOM	89
Chlamydia	89
HSV	89
HPV	89
Syphilis	90
HIV IN EUROPE	90
HEPATITIS B, C IN EUROPE	90
Hepatitis C	90
CHLAMYDIA AND GONORRHEA IN EUROPE	90
Gonorrhea	91
SYPHILIS IN EUROPE	91
HIV IN AFRICA	91
Access to Therapeutics in Africa	92
Hepatitis in Africa	92
RUSSIA, EASTERN EUROPE, CENTRAL ASIA	92
HIV	92
HIV Treatments in the Region	92

TOPIC	PAGE NO.
Hepatitis	92
MIDDLE EAST	93
HIV	93
CHAPTER 8 THE ASIAN MARKET	95
DIAGNOSTIC PRODUCTS	95
<i>TABLE 52 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	95
<i>FIGURE 11 MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE, 2012 AND 2017 (%)</i>	95
STD TREATMENT OPTIONS IN ASIA	96
<i>TABLE 53 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN ASIA BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	97
<i>FIGURE 12 MARKET FOR STD TREATMENT PRODUCTS IN ASIA BY DISEASE, 2012 AND 2017 (%)</i>	97
REGIONAL DISEASE PREVALENCE	98
CHINA	99
HIV	99
HIV Testing and Treatment	99
INDIA	99
HIV	99
Testing	100
Treatment	100
Hepatitis in India	100
AUSTRALIA	100
JAPAN	100
HIV	100
Hepatitis	101
CHAPTER 9 REGULATIONS	103
CREATING DRUG TREATMENTS	103
<i>TABLE 54 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.</i>	103
REGIONAL REGULATIONS	104
THE AMERICAS	104
Surveys	104
Canada	104
EMRA	105
Diagnostic Products in EU	105
ASIA	105
Japan	105
Diagnostic Regulations	105
Pharmaceutical Regulations	106
China	106
India	106
CHAPTER 10 PHARMACEUTICAL TREATMENT PIPELINE	108
EMERGING TRENDS IN DIAGNOSTIC PRODUCTS	108
MICROFLUIDIC PAPER-BASED PRODUCTS	108

TOPIC	PAGE NO.
Microfluidic Detection and Telemedicine	108
EMERGING TRENDS IN PHARMACEUTICAL PRODUCTS	109
CHLAMYDIA	109
HERPES SIMPLEX VIRUS	109
Astellas Helicase Inhibitors	109
HIV/AIDS	109
Merck	110
Gilead Sciences	110
GlaxoSmithKline	110
HEPATITIS	111
Gilead Sciences	111
Janssen Pharmaceuticals/Tibotech Pharmaceuticals	111
Merck	111
Roche	111
Boehringer Ingelheim	112
Vertex Pharmaceuticals	112
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE	112
<i>TABLE 55 SEXUALLY TRANSMITTED DISEASE PHARMACEUTICAL PRODUCT PIPELINE, 2012</i>	113
CHAPTER 11 PATENT ANALYSIS	118
PHARMACEUTICAL PATENTS ISSUED BY COMPANY, APPROVAL DATE AND DISEASE	118
<i>TABLE 56 STD PHARMACEUTICAL PATENTS BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION, AND APPROVAL DATE FEBRUARY 2006-OCTOBER 2012</i>	119
DIAGNOSTIC PATENTS ISSUED BY COMPANY, APPROVAL DATE AND DISEASE	122
<i>TABLE 57 STD DIAGNOSTIC PATENTS BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION AND APPROVAL DATE MARCH 2005-OCTOBER 2012</i>	123
PATENTS ISSUED BY COMPANY	124
<i>TABLE 58 STD PHARMACEUTICAL PRODUCT PATENTS, BY MAJOR COMPANY JANUARY 2005-OCTOBER 2012</i>	124
PATENTS ISSUED BY COUNTRY	125
<i>TABLE 59 STD DIAGNOSIS AND TREATMENT PATENTS BY COUNTRY JANUARY 2005-OCTOBER 2012</i>	125
PATENTS ISSUED BY DISEASE	126
<i>TABLE 60 PATENTS ISSUED FOR DIAGNOSIS AND TREATMENT OF STDS BY DISEASE, MARCH 2005-OCTOBER 2012</i>	126
CHAPTER 12 COMPANY PROFILES	128
ABBOTT LABORATORIES	128
<i>TABLE 61 ABBOTT PHARMACEUTICAL PRODUCTS</i>	128
<i>TABLE 62 ABBOTT DIAGNOSTIC PRODUCTS</i>	128
ALERE	129
<i>TABLE 63 ALERE DIAGNOSTIC PRODUCTS</i>	129
ALFA SCIENTIFIC DESIGNS	130
<i>TABLE 64 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS</i>	130
ATLAS LINK BIOTECH CO, LTD.	130
<i>TABLE 65 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS</i>	131
BAYER AG	131
<i>TABLE 66 BAYER PHARMACEUTICAL PRODUCTS</i>	131

TOPIC	PAGE NO.
BECTON DICKINSON	131
<i>TABLE 67 BECTON DICKINSON DIAGNOSTIC PRODUCTS</i>	132
BIOMERIEUX, INC.	132
<i>TABLE 68 BIOMERIEUX DIAGNOSTIC PRODUCTS</i>	132
BIO-RAD LABORATORIES	132
<i>TABLE 69 BIO-RAD LABORATORIES DIAGNOSTIC PRODUCTS</i>	133
BOEHRINGER INGELHEIM GMBH	133
<i>TABLE 70 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS</i>	133
BRISTOL-MYERS SQUIBB COMPANY	134
<i>TABLE 71 BRISTOL-MEYERS SQUIBB PHARMACEUTICAL PRODUCTS</i>	134
CREATIVE DIAGNOSTICS	134
<i>TABLE 72 CREATIVE DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	135
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS, INC.	135
<i>TABLE 73 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	135
DIASORIN	136
<i>TABLE 74 DIASORIN DIAGNOSTIC PRODUCTS</i>	136
ENZO BIOCHEM	136
<i>TABLE 75 ENZO BIOCHEM DIAGNOSTIC PRODUCTS</i>	137
FIRST DIAGNOSTIC LLC	137
<i>TABLE 76 FIRST DIAGNOSTIC DIAGNOSTIC PRODUCTS</i>	137
GENENTECH (SEE ROCHE)	138
GEN-PROBE, INC. (SEE HOLOGIC)	138
GILEAD SCIENCES, INC.	138
<i>TABLE 77 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS</i>	138
GLAXOSMITHKLINE	138
<i>TABLE 78 GLAXOSMITHKLINE PHARMACEUTICAL PRODUCTS</i>	139
HOLOGIC/GEN-PROBE	139
<i>TABLE 79 HOLOGIC/GEN-PROBE DIAGNOSTIC PRODUCTS</i>	139
HOME ACCESS HEALTH, INC.	140
<i>TABLE 80 HOME ACCESS HEALTH DIAGNOSTIC PRODUCTS</i>	140
IMMUNOSTICS	140
<i>TABLE 81 IMMUNOSTICS DIAGNOSTIC PRODUCTS</i>	140
IND DIAGNOSTIC, INC.	141
<i>TABLE 82 IND DIAGNOSTIC, INC DIAGNOSTIC PRODUCTS</i>	141
INVERNESS MEDICAL INNOVATIONS (SEE ALERE)	141
JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS)	141
<i>TABLE 83 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS</i>	142
MERCK & COMPANY, INC.	142
<i>TABLE 84 MERCK PHARMACEUTICAL PRODUCTS</i>	142
MERIDIAN BIOSCIENCE	143
<i>TABLE 85 MERIDIAN BIOSCIENCE DIAGNOSTIC PRODUCTS</i>	143
NOVARTIS PHARMACEUTICAL CORPORATION	143
<i>TABLE 86 NOVARTIS DIAGNOSTIC PRODUCTS</i>	144
ORASURE TECHNOLOGIES, INC.	144
<i>TABLE 87 ORASURE TECHNOLOGIES DIAGNOSTIC PRODUCTS</i>	144
ORTHO CLINICAL DIAGNOSTICS	144
<i>TABLE 88 ORTHO CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	145

TOPIC	PAGE NO.
PFIZER, INC.	145
<i>TABLE 89 PFIZER PHARMACEUTICAL PRODUCTS</i>	145
PRINCETON BIOMEDITECH CORPORATION	146
<i>TABLE 90 PRINCETON BIOMEDITECH DIAGNOSTIC PRODUCTS</i>	146
QIAGEN BENELUX BV	146
<i>TABLE 91 QIAGEN DIAGNOSTIC PRODUCTS</i>	146
QUIDEL	147
<i>TABLE 92 QUIDEL DIAGNOSTIC PRODUCTS</i>	147
REMEL/THERMOFISHER SCIENTIFIC	147
<i>TABLE 93 REMEL/THERMOFISHER SCIENTIFIC DIAGNOSTIC PRODUCTS</i>	148
ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC.)	148
<i>TABLE 94 ROCHE PHARMACEUTICAL PRODUCTS</i>	148
<i>TABLE 95 ROCHE DIAGNOSTIC PRODUCTS</i>	148
SEKISUI DIAGNOSTICS	149
<i>TABLE 96 SEKISUI DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	149
SHANGHAI KEHUA BIO-ENGINEERING CO, LTD.	149
<i>TABLE 97 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS</i>	149
STANDARD DIAGNOSTICS, INC.	150
<i>TABLE 98 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	150
TRINITY BIOTECH PLC	151
<i>TABLE 99 TRINITY BIOTECH DIAGNOSTIC PRODUCTS</i>	151
VERTEX PHARMACEUTICALS	152
<i>TABLE 100 VERTEX PHARMACEUTICALS PHARMACEUTICAL PRODUCTS</i>	152
VIIV HEALTHCARE	152
<i>TABLE 101 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS</i>	152

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES, THROUGH 2017 (\$ MILLIONS)	4
TABLE 1 MAJOR MANUFACTURERS OF AUTOMATED STD TESTS, 2012	8
TABLE 2 MAJOR MANUFACTURERS OF RAPID AND LABORATORY DIAGNOSTIC STD KITS, 2012	8
TABLE 3 MAJOR MANUFACTURERS OF VACCINES FOR STDS	9
TABLE 4 HPV DIAGNOSTIC PRODUCTS, MANUFACTURER AND MARKET SHARE, 2011 (%)	10
TABLE 5 GONORRHEA DIAGNOSTIC PRODUCT MANUFACTURERS AND PRODUCT NAMES	11
TABLE 6 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS	11
TABLE 7 HEPATITIS A, B AND C DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE OF TEST, 2011 (\$ MILLIONS/%)	12
TABLE 8 MARKET STANDING OF MAJOR HEPATITIS B AND C TREATMENT MANUFACTURERS BY REVENUES, 2011 (\$ MILLIONS)	13
TABLE 9 HIV DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE, 2011 (\$ MILLIONS/%)	14
TABLE 10 HIV/AIDS TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2011 (\$ MILLIONS/%)	15
TABLE 11 NUMBER OF DIAGNOSTIC AND PHARMACEUTICAL MANUFACTURERS, BY DISEASE TREATED, WITH REVENUES AND MARKET SHARE, 2011 (\$ MILLIONS/%)	16
TABLE 12 SELECTED MERGERS AND ACQUISITIONS, 2008-2012 (\$ MILLIONS)	16
TABLE 13 CAUSATIVE ORGANISMS FOR SEXUALLY TRANSMITTED DISEASES	19
TABLE 14 CURRENT DIAGNOSTIC TESTS FOR BACTERIAL VAGINITIS	24
TABLE 15 CURRENT TREATMENTS FOR BACTERIAL VAGINITIS	25
TABLE 16 DIAGNOSTIC TESTS FOR CANDIDIASIS	25
TABLE 17 TREATMENTS FOR VULVOVAGINAL CANDIDIASIS	26
TABLE 18 CURRENT MEDICATIONS USED TO TREAT CHANCROID ULCERS	28
TABLE 19 CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE AND MANUFACTURER, 2012	30
TABLE 20 CURRENT MEDICATIONS USED TO TREAT CHLAMYDIA	31
TABLE 21 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPESBY BRAND NAME, TYPE AND MANUFACTURER, 2012	32
TABLE 22 CURRENT TREATMENTS FOR GENITAL HERPESBY BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012	34
TABLE 23 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME, TYPE AND MANUFACTURER, 2012	35
TABLE 24 MEDICATIONS USED TO TREAT GENITAL WARTS BY BRAND NAME, GENERIC NAME AND MANUFACTURER	36
TABLE 25 CURRENT PRODUCTS USED TO DIAGNOSE GONORRHEA	37
TABLE 26 CURRENT MEDICATIONS USED TO TREAT GONORRHEA	38
TABLE 27 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY BRAND NAME, TYPE AND MANUFACTURER, 2012	40
TABLE 28 VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2012	42
TABLE 29 CDC CLASSIFICATION OF HIV INFECTION	43
TABLE 30 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HIV/AIDS BY BRAND NAME, TYPE AND MANUFACTURER, 2012	45
TABLE 31 HIV LIFE CYCLE	46
TABLE 32 FDA-APPROVED GENERIC DRUGS FOR TREATMENT OF HIV, 2012	47
TABLE 33 CURRENTLY APPROVED PHARMACEUTICAL PRODUCTS FOR TREATMENT OF HIV/AIDS BY BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012	48
TABLE 34 HIV TREATMENT MARKET, BY MANUFACTURER (\$ MILLIONS)	49

TABLE HEADING	PAGE NO.
TABLE 35 CURRENT TREATMENTS FOR PEDICULOSIS PUBIS BRAND NAME, GENERIC NAME AND MANUFACTURER	53
TABLE 36 CURRENT TREATMENTS FOR PID BRAND NAME, GENERIC NAME AND MANUFACTURER	54
TABLE 37 CURRENT TREATMENTS FOR SCABIES BRAND NAME, GENERIC NAME AND MANUFACTURER	56
TABLE 38 STAGES OF SYPHILIS	57
TABLE 39 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY BRAND NAME, TYPE AND MANUFACTURER, 2012	58
TABLE 40 DIAGNOSTIC ASSAYS FOR DETECTION OF TRICHOMONAS WITH BRAND NAME, TYPE AND MANUFACTURER	60
TABLE 41 CURRENT MEDICATIONS FOR THE TREATMENT OF TRICHOMONAS	61
TABLE 42 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT STDS BY DISEASE, THROUGH 2017 (\$ MILLIONS)	67
TABLE 43 PROJECTED GLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	68
TABLE 44 PROJECTED GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	70
TABLE 45 PROJECTED GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	70
TABLE 46 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE AMERICAS, THROUGH 2017 (\$ MILLIONS)	76
TABLE 47 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE AMERICAS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)	78
TABLE 48 ESTIMATED ANNUAL NUMBER OF PREGNANT WOMEN WITH AN STD IN THE U.S.	80
TABLE 49 ANNUAL INCIDENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., 2010 (PER 100,000 PEOPLE)	81
TABLE 50 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE EMRA, THROUGH 2017 (\$ MILLIONS)	86
TABLE 51 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE EMRA BY DISEASE, THROUGH 2017 (\$ MILLIONS)	87
TABLE 52 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE, THROUGH 2017 (\$ MILLIONS)	95
TABLE 53 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN ASIA BY DISEASE, THROUGH 2017 (\$ MILLIONS)	97
TABLE 54 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.	103
TABLE 55 SEXUALLY TRANSMITTED DISEASE PHARMACEUTICAL PRODUCT PIPELINE, 2012	113
TABLE 56 STD PHARMACEUTICAL PATENTS BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION, AND APPROVAL DATE FEBRUARY 2006-OCTOBER 2012	119
TABLE 57 STD DIAGNOSTIC PATENTS BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION AND APPROVAL DATE MARCH 2005-OCTOBER 2012	123
TABLE 58 STD PHARMACEUTICAL PRODUCT PATENTS, BY MAJOR COMPANY JANUARY 2005-OCTOBER 2012	124
TABLE 59 STD DIAGNOSIS AND TREATMENT PATENTS BY COUNTRY JANUARY 2005-OCTOBER 2012	125
TABLE 60 PATENTS ISSUED FOR DIAGNOSIS AND TREATMENT OF STDS BY DISEASE, MARCH 2005-OCTOBER 2012	126
TABLE 61 ABBOTT PHARMACEUTICAL PRODUCTS	128
TABLE 62 ABBOTT DIAGNOSTIC PRODUCTS	128
TABLE 63 ALERE DIAGNOSTIC PRODUCTS	129
TABLE 64 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS	130

TABLE HEADING	PAGE NO.
TABLE 65 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS	131
TABLE 66 BAYER PHARMACEUTICAL PRODUCTS	131
TABLE 67 BECTON DICKINSON DIAGNOSTIC PRODUCTS	132
TABLE 68 BIOMERIEUX DIAGNOSTIC PRODUCTS	132
TABLE 69 BIO-RAD LABORATORIES DIAGNOSTIC PRODUCTS	133
TABLE 70 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS	133
TABLE 71 BRISTOL-MEYERS SQUIBB PHARMACEUTICAL PRODUCTS	134
TABLE 72 CREATIVE DIAGNOSTICS DIAGNOSTIC PRODUCTS	135
TABLE 73 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS	135
TABLE 74 DIASORIN DIAGNOSTIC PRODUCTS	136
TABLE 75 ENZO BIOCHEM DIAGNOSTIC PRODUCTS	137
TABLE 76 FIRST DIAGNOSTIC DIAGNOSTIC PRODUCTS	137
TABLE 77 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS	138
TABLE 78 GLAXOSMITHKLINE PHARMACEUTICAL PRODUCTS	139
TABLE 79 HOLOGIC/GEN-PROBE DIAGNOSTIC PRODUCTS	139
TABLE 80 HOME ACCESS HEALTH DIAGNOSTIC PRODUCTS	140
TABLE 81 IMMUNOSTICS DIAGNOSTIC PRODUCTS	140
TABLE 82 IND DIAGNOSTIC, INC DIAGNOSTIC PRODUCTS	141
TABLE 83 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS	142
TABLE 84 MERCK PHARMACEUTICAL PRODUCTS	142
TABLE 85 MERIDIAN BIOSCIENCE DIAGNOSTIC PRODUCTS	143
TABLE 86 NOVARTIS DIAGNOSTIC PRODUCTS	144
TABLE 87 ORASURE TECHNOLOGIES DIAGNOSTIC PRODUCTS	144
TABLE 88 ORTHO CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS	145
TABLE 89 PFIZER PHARMACEUTICAL PRODUCTS	145
TABLE 90 PRINCETON BIOMEDITECH DIAGNOSTIC PRODUCTS	146
TABLE 91 QIAGEN DIAGNOSTIC PRODUCTS	146
TABLE 92 QUIDEL DIAGNOSTIC PRODUCTS	147
TABLE 93 REMEL/THERMOFISHER SCIENTIFIC DIAGNOSTIC PRODUCTS	148
TABLE 94 ROCHE PHARMACEUTICAL PRODUCTS	148
TABLE 95 ROCHE DIAGNOSTIC PRODUCTS	148
TABLE 96 SEKISUI DIAGNOSTICS DIAGNOSTIC PRODUCTS	149
TABLE 97 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS	149
TABLE 98 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS	150
TABLE 99 TRINITY BIOTECH DIAGNOSTIC PRODUCTS	151
TABLE 100 VERTEX PHARMACEUTICALS PHARMACEUTICAL PRODUCTS	152
TABLE 101 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS	152

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES, 2011 AND 2017 (%)	4
FIGURE 1 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011 (%)	13
FIGURE 2 MARKET SHARE OF LEADING COMPANIES IN THE HIV/AIDS TREATMENT MARKET, 2011 (%)	15
FIGURE 3 2011 MARKET SHARE FOR BRANDED HIV DRUGS, BY MANUFACTURER (%)	50
FIGURE 4 MARKET SHARE FOR TYPES OF TESTS USED TO DIAGNOSE STDs, 2012 (%)	66
FIGURE 5 GLOBAL STD DIAGNOSTIC MARKET, BY REGION 2012 AND 2017 (%)	69
FIGURE 6 GLOBAL STD PHARMACEUTICAL MARKET BY REGION 2012 AND 2017 (%)	71
FIGURE 7 MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE AMERICAS BY DISEASE, 2012 AND 2017 (%)	76
FIGURE 8 MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE AMERICAS BY DISEASE, 2012 AND 2017 (%)	79
FIGURE 9 MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE EMRA BY DISEASE, 2012 AND 2017 (%)	86
FIGURE 10 MARKET FOR STD TREATMENT PRODUCTS IN THE EMRA BY DISEASE, 2012 AND 2017 (%)	88
FIGURE 11 MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE, 2012 AND 2017 (%)	95
FIGURE 12 MARKET FOR STD TREATMENT PRODUCTS IN ASIA BY DISEASE, 2012 AND 2017 (%)	97